Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants
Generalized Anxiety Disorder (GAD): A First-in-Human Single Ascending Dose and Food Effect Study of ABBV-932 in Healthy Adult Subjects
Sponsor: AbbVie
This PHASE1 trial investigates Generalized Anxiety Disorder (GAD) and Healthy Participants and is currently completed. AbbVie leads this study, which shows 10 recorded versions since 2023 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
Feb 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — Jan 2024 [monthly]
Recruiting PHASE1
-
May 2023 — Nov 2023 [monthly]
Recruiting PHASE1
-
Mar 2023 — May 2023 [monthly]
Recruiting PHASE1
First recorded
Feb 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
- Gedeon Richter Plc.
For direct contact, visit the study record on ClinicalTrials.gov .